Verve Therapeutics (VERV) stock surged as promising trial data for cholesterol therapy VERVE-102 prompted Cantor Fitzgerald ...

Cantor Fitzgerald analyst C J Muse reiterated a Buy rating on Nvidia (NVDA – Research Report) yesterday and set a price target of $200.00.Stay ...

Cantor Fitzgerald lowered the firm’s price target on Amazon.com (AMZN) to $230 from $270 and keeps an Overweight rating on the shares. The Q1 ...

On Monday, Cantor Fitzgerald reaffirmed its Overweight rating on Tesla shares (NASDAQ:TSLA), a prominent player in the automotive industry with a market capitalization of $811.56 billion.

On Friday, Cantor Fitzgerald reaffirmed its Overweight rating on Zai Lab (NASDAQ:ZLAB) despite recent market pressures. Trading at $24.32, Zai Lab stock has experienced significant downward ...

Cantor Fitzgerald views Bob Duggan’s, Summit Therapeutics (SMMT) co-CEO and Chairman, stock option exercise “quite unusual” and “quite bullish” for the shares. Duggan’ exercised ...

Cantor Fitzgerald Large Cap Focused Fund earns an Above Average Process Pillar rating. The main driver of the rating is the parent firm's five-year risk-adjusted success ratio of 81%. The measure ...

We recently published a list of 14 AI Stocks Catching Wall Street’s Attention. In this article, we are going to take a look at where NVIDIA Corporation (NASDAQ:NVDA) stands against other AI ...